IO Frontiers World 2019


Francesco Galimi, MD, PhD

Dr Francesco Galimi, MD, PhD

Global Product General Manager, Early Development, Amgen, Inc.

Francesco Galimi, MD PhD is Executive Medical Director and General Manager, Early Development at Amgen, where he is responsible for the company’s early myeloma pipeline.

Dr. Galimi began his industry career at Amgen in 2004, and he held a number of positions in research, early development, and clinical development, most recently as Medical Director, Clinical Research. He then spent three years at Novartis, as Executive Medical Director, Oncology Translational Medicine, before joining Onyx in 2014 as Head of Clinical Development.

Dr. Galimi holds an MD, a PhD in molecular oncology, and a board certification in medical oncology from the University of Torino, Italy. He spent many years in academia before joining the industry, and he still holds an academic appointment in Italy as associate professor of histology and cell biology.

  • "Great venue to solidify and harmonize on the current challenges facing this sector - in real time. The caliber of the speakers and session contents was premier. “
    Dolores Baksh
    Innovation Leader, GE Healthcare
  • “A great event to learn about the hurdles that are needed to be overcome to get through the clinic.”
    Devin Bridgen
    Scientist, strategic partnerships, SQZ Biotech
  • "It was a great opportunity to share current data and thinking about the development of therapeutics directed at modulating the immune response to cancer."
    Lance Leopold
    Vice President, Head of Oncology Development, Incyte Corporation
  • "Phacilitate provides a unique forum, bringing together research, process development, and commercial leaders on the cutting edge of cell, gene, and immunotherapy. A great conference for anyone wanting a comprehensive view of the field."
    Dr James Trager
    Vice President, Research & Product Development, Dendreon
  • “In the rapidly moving Advanced Therapy market, Phacilitate remains one of the premier events.”
    David James
    CEO, Scinogy